What Placebo Response Data in Atopic Dermatitis Trials are Actually Telling Us
Placebo response, which has emerged as an important determinant of interpretability and success in atopic dermatitis (AD) clinical trials, is frequently a predictable consequence of conducting high-quality clinical studies in a disease characterized by inherent variability over time. Modern AD programs increasingly acknowledge placebo response as a structural feature rather than an anomaly. Adaptive designs, […]
Placebo Response in Clinical Trials for Hidradenitis Suppurativa
Potential contributors to placebo rates in hidradenitis suppurativa (HS) clinical trials include underlying disease variability, the relative lack of efficacy of current therapies, and the requirement for rescue therapy and/or concomitant medications. More specifically, the contributors to placebo response lie in the difficulty in evaluating disease severity in HS, lack of non-physician or patient-assessed objective measures […]
Durability of response to icotrokinra for high-impact site psoriasis: 1-year ICONIC-TOTAL findings
Authors: Warren, R. B., Gooderham, M., Lain, E., Bissonnette, R., Huang, Y. H., Ringuet, J., Hoffmann, M., Pinter, A., Merola, J. F., Rubens, J. H., Fan, D., Hsu, M. C., Li, S., Yang, Y. W., DeKlotz, C. M. C., & Song, E. J. Read more on pubmed
Maintenance of Response With Icotrokinra, a Targeted Oral Peptide, for the Treatment of Moderate-to-Severe Plaque Psoriasis: Randomized Treatment Withdrawal in Adults From the Phase 3, ICONIC-LEAD Study
Authors: Soung, J., Cui, Y., Bissonnette, R., Lebwohl, M. G., GonzĂĄlez-Cantero, Ă., Pinter, A., Rich, P., Prajapati, V. H., Miller-Kassamali, M., Cafone, J., Jiang, J., Li, S., Yang, Y. W., & Pink, A. E. Read more on pubmed
International Eczema Council Definitions of Low Disease Activity and Remission in Atopic Dermatitis: A Consensus Statement
Innovaderm/Indero founder Dr. Robert Bissonnette has coauthored the International Eczema Councilâs globally endorsed, expert-derived framework defining low disease activity and remission in atopic dermatitis, in JAMA Dermatology, April 2026. These standardized, clinically meaningful definitions provide a foundation for harmonized trial design, regulatory evaluation, and longitudinal comparative effectiveness research. Authors: Merola, J. F., Childs, B. A., Bartley, B. R., Bissonnette, R., Bieber, T., Guttman-Yassky, E., Paller, A. S., […]
Navigating Placebo Response in Dermatology Trials â AAD Breakfast Event
Innovaderm was in New Orleans for the 2023 edition of the AAD congress and hosted its 4th Breakfast Event: Spotlight on Hidradenitis Suppurativa (HS).
Burden and Etiopathogenesis of Chronic Hand Eczema: A Complex Interplay of Genes, Environment, and Exposures
Authors: Molin, S., Yeung, J., & Bissonnette, R Different morphological and etiological subtypes of CHE appear to have overlapping and distinct features related to gene expression, proteomics, inflammatory biomarkers, and metagenomics, but data are limited and derived from small patient cohorts. The available evidence points to the broad activation of immune pathways implicated in JAK-STAT […]
The Gut Microbiome of Non-Atopic Chronic Hand Eczema (CHE) Subjects is Distinct and Enriched in Immuno-Modulatory Bacteria Species compared to Atopic-CHE and Healthy Subjects
Authors: Bissonnette R, Salem Y, Palijan A, Maari C, Proulx ES, Prifti DK, Hunter S, Routy B,Elkrief A. Read more on pubmed
Summary of Research: Efficacy and Safety of Delgocitinib Cream in Adults with Moderate to Severe Chronic Hand Eczema (DELTA 1 and DELTA 2): Results from Multicentre, Randomised, Controlled, Double-Blind, Phase 3 Trials
Authors: Bissonnette R, Albreiki F, Ehst BD, Al Hammadi A, Schliemann S, Yang B, Zhang J, BunickCG. Read more on pubmed
Dupilumab Treatment Up to 5 Years Shows No Clinically Meaningful Changes in Laboratory Parameters in Adults with Moderate-to-Severe Atopic Dermatitis
Authors: Simpson EL, Bissonnette R, Deleuran M, Nakahara T, Galus R, de Bruin-Weller M, Coleman A, van Spall M, Chen Z, Avetisova E, Bastian M, Khokhar FA. Read more on pubmed
